This morning’s Observer column:
…As a consequence, a powerful technology with great potential for good is at the moment deployed mainly for privatised gain. In the process, it has been characterised by unregulated premature deployment, algorithmic bias, reinforcing inequality, undermining democratic processes and boosting covert surveillance to toxic levels. That it doesn’t have to be like this was vividly demonstrated last week with a report in the leading biological journal Cell of an extraordinary project, which harnessed machine learning in the public (as compared to the private) interest. The researchers used the technology to tackle the problem of bacterial resistance to conventional antibiotics – a problem that is rising dramatically worldwide, with predictions that, without a solution, resistant infections could kill 10 million people a year by 2050.